DATATOP: A decade of neuroprotective inquiry
Identifieur interne : 001F14 ( Main/Exploration ); précédent : 001F13; suivant : 001F15DATATOP: A decade of neuroprotective inquiry
Auteurs : ShoulsonSource :
- Annals of Neurology [ 0364-5134 ] ; 1998-09.
Abstract
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.
Url:
DOI: 10.1002/ana.410440724
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B1EF59AC84F0685F3556CF98C6A1472513B16C66</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/ana.410440724</idno><idno type="url">https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000194</idno><idno type="wicri:Area/Main/Curation">000159</idno><idno type="wicri:Area/Main/Exploration">001F14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name><affiliation><wicri:noCountry code="subField">NY.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-09">1998-09</date><biblScope unit="volume">44</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">1</biblScope><biblScope unit="page" from="S160">S160</biblScope><biblScope unit="page" to="S166">S166</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">B1EF59AC84F0685F3556CF98C6A1472513B16C66</idno><idno type="DOI">10.1002/ana.410440724</idno><idno type="ArticleID">ANA410440724</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B1EF59AC84F0685F3556CF98C6A1472513B16C66
|texte= DATATOP: A decade of neuroprotective inquiry
}}
| This area was generated with Dilib version V0.6.23. |  |